Shelia Violette Sells 2,815 Shares of Q32 Bio (NASDAQ:QTTB) Stock

Q32 Bio Inc. (NASDAQ:QTTB) insider Shelia Violette sold 2,815 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total transaction of $12,695.65. Following the completion of the transaction, the insider owned 55,569 shares in the company, valued at $250,616.19. The trade was a 4.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Q32 Bio Trading Down 4.2%

Shares of NASDAQ:QTTB opened at $4.56 on Friday. The company has a 50-day moving average price of $3.81 and a 200-day moving average price of $2.90. The company has a market cap of $56.09 million, a price-to-earnings ratio of -1.33 and a beta of 0.16. Q32 Bio Inc. has a 12 month low of $1.35 and a 12 month high of $6.37.

More Q32 Bio News

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Analysts Set New Price Targets

QTTB has been the topic of a number of recent analyst reports. HC Wainwright began coverage on Q32 Bio in a research report on Wednesday. They issued a “buy” rating and a $13.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Q32 Bio currently has an average rating of “Hold” and a consensus price target of $14.00.

Institutional Trading of Q32 Bio

Large investors have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in shares of Q32 Bio during the 4th quarter worth approximately $68,000. Opaleye Management Inc. bought a new stake in shares of Q32 Bio during the fourth quarter valued at approximately $708,000. ADAR1 Capital Management LLC bought a new stake in shares of Q32 Bio during the fourth quarter valued at approximately $66,000. Jane Street Group LLC purchased a new stake in Q32 Bio in the fourth quarter worth $84,000. Finally, HRT Financial LP raised its holdings in Q32 Bio by 66.5% in the fourth quarter. HRT Financial LP now owns 24,698 shares of the company’s stock worth $81,000 after purchasing an additional 9,862 shares in the last quarter. 31.32% of the stock is owned by institutional investors.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.